Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Richard Dillon, Mariam Amer et al.|Blood|2023Cited by 65
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AMLJad Othman, Richard Dillon, Nicola Potter et al.|Leukemia|2023Cited by 48
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHSJad Othman, Richard Dillon, Ho Pui Jeff Lam et al.|Blood Neoplasia|2024Cited by 36
Outcomes with single-agent gilteritinib for relapsed or refractory <i>FLT3</i>-mutant AML after contemporary induction therapyJad Othman, Richard Dillon, Angela Hwang et al.|Blood Advances|2024Cited by 10